ABSTRACT
Objective· To investigate the relationship between pathological myopia and classification of vitreoretinal interface features using enhanced vitreous imaging optical coherence tomography (EVI-OCT). Methods · High myopia patients were included from 2015 to 2016. All participants underwent standardized medical interviews and ophthalmic examination. Results · The included eyes were divided into two groups of pathological myopia and simple high myopia based on myopic macular degeneration observed on fundus photography . There were four types of vitreoretinal interface changes demonstrated on EVI-OCT scans in included eyes: Type1, posterior precortical vitreous pockets (PPVP), Type2, partial posterior vitreous detachment with vitreous adhesion (VA), Type 3, epiretinal membrane (ERM), and Type 4, no traction (NT). Pathological myopia was mostly detected in VA, ERM, and NT groups. Conclusion · EVI-OCT was able to demonstrate the early changes of vitreoretinal interface in high myopia eyes. Vitreous adhesions and traction detected by OCT may facilitate the occurrence of pathological myopia.
ABSTRACT
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years old. Vascular endothelial growth factor (VEGF) plays a critical role in the development of wet AMD. At present, the main treatment is monoclonal antibodies against VEGF, but the maintenance time is short, and it requires frequent and repeated treatment. Recently with the fast development of gene therapy, soluble VEGF receptor -1 (sFlt-1), which may act as one of the biomarkers of AMD, is gaining more attention. sFlt-1 is the unique endogenous VEGF inhibitor. With the development of AMD, serum sFlt-1 decreases markedly. This article reviewed the molecular structure and pathophysiological function of sFlt-1, its role in the advance of AMD, and the preclinical studies as well as clinical studies about it.
ABSTRACT
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years old. Vascular endothelial growth factor (VEGF) plays a critical role in the development of wet AMD. At present, the main treatment is monoclonal antibodies against VEGF, but the maintenance time is short, and it requires frequent and repeated treatment. Recently with the fast development of gene therapy, soluble VEGF receptor -1 (sFlt-1), which may act as one of the biomarkers of AMD, is gaining more attention. sFlt-1 is the unique endogenous VEGF inhibitor. With the development of AMD, serum sFlt-1 decreases markedly. This article reviewed the molecular structure and pathophysiological function of sFlt-1, its role in the advance of AMD, and the preclinical studies as well as clinical studies about it.